<DOC>
	<DOCNO>NCT00730925</DOCNO>
	<brief_summary>The primary objective open-label , single arm Phase II trial explore efficacy BIBW 2992 define objective response rate ( CR , PR ) determine RECIST criterion , patient advance NSCLC Stage IIIB IV whose tumour harbour activate mutation within exon 18 exon 21 EGFR receptor , patient mutation HER2/neu receptor patient EGFR FISH positive tumour EGFR mutation .</brief_summary>
	<brief_title>Single-arm Trial BIBW 2992 ( Afatinib ) Demographically Genotypically Selected NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : 1. patient pathologically confirm diagnosis NSCLC stage IIIB/IV adeno bronchoalveolar carcinoma ( BAC ) 2. non smoker patient patient smoke less 15 pack year stop smoke least one year diagnosis ( except patient her2neu mutation ) 3. presence activate mutation ( ) exon 18 exon 21 EGFR HER2neureceptor confirm direct DNA sequence NSCLC tumor tissue increase copy number EGFR gene determine FISH analysis 4. prior treatment 3 line chemotherapy except HER2neu patient ( restriction ) prior EGFR TKI therapy EGFR mutation negative FISCH positive patient 5. patient least one tumor lesion accurately measure CTscan MRI least one dimension long diameter record &gt; equal 20 mm use conventional technique &gt; equal 10 mm spiral CT scan 6. male female patient age equal 18 year 7. life expectancy least 3 month 8. write informed consent consistent ICHGCP guideline 9 . ECOG performance score 0 , 1 2 Exclusion criterion : 1. 3 prior cytotoxic chemotherapy treatment regimen relapse metastatic NSCLC , except patient HER2neu mutation may receive prior therapy 2 . Any chemo , hormone immunotherapy within past 4 week within less 4 halflives previous drug prior treatment trial drug and/or persistence toxicity prior anticancer therapy deem clinically relevant 3. brain metastasis symptomatic ; patient treat asymptomatic brain metastasis eligible stable brain disease least 4 week without requirement steroid antiepileptic therapy 4. significant recent acute gastrointestinal disorder diarrhea major symptom e.g . Crohn 's disease , malabsorption CTCAE Grade &gt; 2 diarrhea etiology baseline 5. patient lifethreatening illness organ system dysfunction , opinion investigator , would either compromise patient safety interfere evaluation safety test drug 6. malignancy diagnose within past 5 year ( non melanomatous skin cancer situ cervical cancer ) 7. radiotherapy within past 2 week prior treatment trial drug 8. patient serious active infection ( i.e. , require IV antibiotic , antifungal , antiviral agent ) 9. patient know HIV , active hepatitis B active hepatitis C 10. know suspect active drug alcohol abuse 11. woman childbearing potential men able father child unwilling use medically acceptable method contraception trial 12. pregnancy breast feed 13. patient unable comply protocol 14. history clinically significant uncontrolled cardiac disease , include congestive heart failure , angina , myocardial infarction , arrhythmia , include New York Heart Association ( NYHA ) functional classification 3 15 . Cardiac leave ventricular function rest ejection fraction le 50 % measure multigated blood pool image heart ( MUGA scan ) Echocardiogram . 16 . Absolute neutrophil count ( ANC ) less 1500/mm³ . 17 . Platelet count less 100 000 / mm³ . 18 . Bilirubin great 1.5 mg / dl ( &gt; 26 µmol / L , SI unit equivalent ) . 19 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) . 20 . Serum creatinine great 1.5 time upper normal limit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>